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Abstract
Background: Cancer survivors face an increased likelihood of being subsequently diagnosed with another cancer.
The aim of this study was to quantify the relative risk of survivors developing a second primary cancer in
Queensland, Australia.
Methods: Standardised incidence rates stratified by type of first primary cancer, type of second primary cancer, sex,
age at first diagnosis, period of first diagnosis and follow-up interval were calculated for residents of Queensland,
Australia, who were diagnosed with a first primary invasive cancer between 1982 and 2001 and survived for a
minimum of 2 months.
Results: A total of 23,580 second invasive primary cancers were observed over 1,370,247 years of follow-up among
204,962 cancer patients. Both males (SIR = 1.22; 95% CI = 1.20-1.24) and females (SIR = 1.36; 95% CI = 1.33-1.39)
within the study cohort were found to have a significant excess risk of developing a second cancer relative to the
incidence of cancer in the general population. The observed number of second primary cancers was also higher
than expected within each age group, across all time periods and during each follow-up interval.
Conclusions: The excess risk of developing a second malignancy among cancer survivors can likely be attributed
to factors including similar aetiologies, genetics and the effects of treatment, underlining the need for ongoing
monitoring of cancer patients to detect subsequent tumours at an early stage. Education campaigns developed
specifically for survivors may be required to lessen the prevalence of known cancer risk factors.
Background
The number of people being diagnosed with cancer
worldwide is rising sharply, mainly as a result of popula-
tion growth, ageing and increases in the prevalence of
several lifestyle factors related to cancer risk [1,2]. Com-
bined with improvements in survival, due in part to
both earlier detection and better treatment, more people
are living with a diagnosis of cancer than ever before,
and this increasing trend is likely to continue [3].
One of the consequences of surviving cancer is the
increased likelihood of being diagnosed with a second
primary cancer. Among other things, these second can-
cers may be the result of lifestyle choices, genetics, envir-
onmental exposures (all of which may also be related to
the first cancer) and late effects of treatment [3,4].
For the patient and their treating clinician, quantifying
and characterising the risks for second malignancies has
important implications for screening (particularly when
effective screening methods such as mammography are
available), prevention strategies and counselling [3,5,6].
Identifying cancers which have an elevated likelihood of
occurring together is also a useful starting point for
investigating possible shared aetiologies and mechanisms
of carcinogenesis [7].
This study reports for the first time the relative risks
of a second cancer for people diagnosed with a first pri-
mary cancer in Queensland, Australia.
Methods
A retrospective cohort design was used for this analysis.
De-identified case records were obtained from the
Queensland Cancer Registry (QCR), a population-based
registry covering the entire state. All public and private
hospitals, nursing homes and pathology services
throughout Queensland are required by law to notify
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except for non-melanoma skin cancers [8].
The study cohort included all Queensland residents
diagnosed with a first primary invasive cancer between
1982 and 2001 who survived for a minimum of
2 months. Since classifications for childhood cancers are
different to adult cancers [9], we decided to restrict the
cohort to people who were 15 years or older at the time
of first diagnosis. A small number of records were
excluded because information was missing for age (n =
20), or because the person was known to have had a
first primary cancer diagnosed prior to 1982 (n = 76).
The cohort was followed up until 31
st December 2006
(allowing a potential minimum of five years and a maxi-
mum of 25 years after the initial diagnosis) to ascertain
the occurrence of second primary invasive cancers. His-
tologically similar cases of cancer at the same body site
were included, unless the medical record indicated that
the tumour was recurrent or metastatic. Synchronous
primary cancers (those diagnosed within 2 months of
the first primary cancer) [10] were excluded because
they were more likely to have been diagnosed as a result
of detection bias [6]. Third or subsequent primary can-
cers were not considered in this analysis.
Cancers of various body sites were analysed in a sepa-
rate group if they averaged more than 100 eligible first
primary cancers per year. These cancers are shown in
Table 1. Cancers of the head and neck (ICD-O-3 topo-
graphy codes C00-C14 and C30-C32) were grouped
together prior to analysis, as were cancers of the colon
and rectum (C18-C20 and C218). All remaining types of
cancer were analysed collectively in the category labelled
“Other”, including cases where site was ill-defined or
unknown.
Person years at risk (PYAR) among people diagnosed
with a first primary cancer was calculated as the time
from 2 months after diagnosis until 31 December 2006,
date of death or date of diagnosis of a second primary
cancer, whichever came first. Data were stratified by
type of first primary cancer, type of second primary can-
cer, sex, age at first diagnosis, period of first diagnosis
and follow-up interval. Analysis by period of first diag-
nosis was restricted to five years of follow-up to allow
more consistent comparisons across time. The expected
number of second primary cancers in each stratum was
calculated by multiplying the sum of PYAR by the can-
cer-specific incidence rate experienced by the general
Queensland population, matched by sex, age group and
time period. Standardised incidence ratios (SIRs) were
then obtained by dividing the observed number of cases
of second primary cancer by the expected number. The
SIR is thus used to estimate the risk of a cancer patient
developing a second primary malignancy relative to the
incidence of cancer among the general population.
Confidence intervals (CIs) for the SIRs were derived
from the Poisson distribution [11] and calculated at the
95% level of certainty.
All analyses were conducted using SAS v9.2 for Win-
dows. Data required for this study was non-identifiable
so no ethics committee approval was necessary.
Results
The basic characteristics of the study cohort are sum-
marised in Table 1. Among the 204,962 eligible cancer
patients, a total of 23,580 second invasive primary can-
cers were observed during 1,370,247 years of follow-up
(median follow-up = 5.5 years per person, interquartile
range = 1.3 to 10.2 years per person). In terms of abso-
lute numbers, second primary cancers were more com-
mon among males and increased with older age, which is
consistent with the distribution of first primary cancers.
About one in ten (10.6%) of the second primary cancers
were diagnosed within a year of the first diagnosis, while
more than one in five (20.6%) were diagnosed at least
10 years afterwards. The highest proportions of second
primary cancers occurred following an initial diagnosis of
melanoma (21.6%), colorectal cancer (12.9%), prostate
cancer (12.7%), or female breast cancer (12.6%).
Relative risk of second primary cancers by sex
Compared to the incidence of cancer in the general
Queensland population, both males (SIR = 1.22; 95% CI
= 1.20-1.24) and females (SIR = 1.36; 95% CI = 1.33-
1.39) in the study cohort exhibited an increased risk of
developing a second primary cancer (Table 2). Signifi-
cantly increased relative risks of invasive cancer were
recorded among males following diagnosis of head and
neck cancer, oesophageal cancer, lung cancer, mela-
noma, kidney cancer, bladder cancer, thyroid cancer,
non-Hodgkin lymphoma, lymphoid leukaemia or mye-
loid leukaemia. In contrast, males initially diagnosed
with either prostate or stomach cancer subsequently
experienced a significantly lower risk of cancer com-
pared to the general population.
Within the female cohort, the relative risk of a second
cancer was higher for those diagnosed with head and
neck cancer, colorectal cancer, lung cancer, melanoma,
breast cancer, cervical cancer, uterine cancer, kidney can-
cer, bladder cancer, thyroid cancer, non-Hodgkin lym-
phoma, lymphoid leukaemia or myeloid leukaemia.
There were no types of cancer for which female survivors
had a significantly lower risk of developing a second inva-
sive cancer in relation to the general population.
Relative risk of second primary cancers by age group at
diagnosis
The risk of a second malignancy was higher in compari-
son to the general population for each of the three age
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tended to decrease as age at first diagnosis increased
(Table 3) - 15-49 years (SIR = 1.84; 95% CI = 1.77-1.90),
50-64 years (SIR = 1.39; 95% CI = 1.36-1.42) and
65 years and older (SIR = 1.23; 95% CI = 1.20-1.25). Dif-
ferent patterns emerged within the various cancer-speci-
fic cohorts. An elevated relative risk across all three age
groups was found following head and neck cancer, lung
cancer, melanoma, female breast cancer, cervical cancer,
kidney cancer, bladder cancer, non-Hodgkin lymphoma
and lymphoid leukaemia. For oesophageal and colorectal
cancer, significantly increased relative risks were only
observed among those aged under 65 years at first diag-
nosis, while for pancreatic and brain cancers the risk
was elevated in the younger age groups but was lower
than expected for people aged 65 years and over.
Table 1 Characteristics of the study cohort
First Primary Cancers Second Primary Cancers
Number of cases % Number of cases %
Total 204,962 100.0 23,580 100.0
Sex
Males 110,961 54.1 14,388 61.0
Females 94,001 45.9 9,192 39.0
Age at first diagnosis
15-49 years 41,690 20.3 3,150 13.4
50-64 years 60,573 29.6 7,687 32.6
65 years and over 102,699 50.1 12,743 54.0
Period of first diagnosis
1982-1986 36,216 17.7 4,716 20.0
1987-1991 43,904 21.4 5,841 24.8
1992-1996 57,381 28.0 6,972 29.6
1997-2001 67,461 32.9 6,051 25.7
Follow-up interval
2 months to less than 1 year n.a. 2,511 10.6
1 year to less than 5 years n.a. 8,924 37.8
5 years to less than 10 years n.a. 7,286 30.9
10 years or longer n.a. 4,859 20.6
Type of first primary cancer
Head and neck (C00-C14,C30-C32) 10,942 5.3 1,989 8.4
Oesophagus (C15) 2,075 1.0 105 0.4
Stomach (C16) 4,103 2.0 206 0.9
Colorectal (C18-C20,C218) 27,814 13.6 3,046 12.9
Pancreas (C25) 2,817 1.4 49 0.2
Lung (C33-C34) 17,347 8.5 729 3.1
Melanoma (C44,M872-M879) 29,289 14.3 5,092 21.6
Breast - female (C50) 26,725 13.0 2,962 12.6
Cervix (C53) 3,492 1.7 300 1.3
Uterus (C54) 3,527 1.7 409 1.7
Ovary (C56) 2,864 1.4 164 0.7
Prostate (C61) 23,122 11.3 3,006 12.7
Kidney (C64-C66,C68) 4,927 2.4 655 2.8
Bladder (C67) 8,719 4.3 1,680 7.1
Brain & CNS (C70-C72) 2,566 1.3 50 0.2
Thyroid (C73) 2,302 1.1 215 0.9
Non-Hodgkin lymphoma (M967-M972) 6,618 3.2 689 2.9
Lymphoid leukaemia (M982-M983) 2,645 1.3 422 1.8
Myeloid leukaemia (M984-M993) 2,195 1.1 125 0.5
Myeloma/PCT (M973) 2,174 1.1 134 0.6
Other 18,699 9.1 1,553 6.6
n.a. = not applicable; CNS = central nervous system; PCT = plasma cell tumours.
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within each age group for males with prostate cancer,
although the SIR was not statistically significant for
those aged 15-49 years.
Relative risk of second primary cancers by time period of
first diagnosis
There was some evidence that the more recently a first
primary cancer was diagnosed the higher the relative
Table 2 Relative risk of second primary cancer by type of first primary cancer and sex, Queensland, 1982-2006
Sex
Males Females
First primary cancer Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Head and neck 1,620 1.70
(1.62-1.79)
369 1.84
(1.66-2.04)
Oesophagus 78 1.43
(1.13-1.79)
27 1.06
(0.70-1.54)
Stomach 150 0.83
(0.70-0.98)
56 1.00
(0.75-1.30)
Colorectal 1,899 1.04
(0.99-1.08)
1,147 1.08
(1.02-1.15)
Pancreas 31 0.92
(0.63-1.31)
18 0.85
(0.50-1.34)
Lung 552 1.18
(1.08-1.28)
177 1.41
(1.21-1.64)
Melanoma 3,267 1.77
(1.71-1.83)
1,825 1.70
(1.62-1.78)
Breast - female n.a. n.a. 2,962 1.31
(1.27-1.36)
Cervix n.a. n.a. 300 1.36
(1.21-1.52)
Uterus n.a. n.a. 409 1.16
(1.05-1.28)
Ovary n.a. n.a. 164 1.12
(0.95-1.30)
Prostate 3,006 0.83
(0.80-0.86)
n.a. n.a.
Kidney 434 1.39
(1.27-1.53)
221 1.69
(1.47-1.93)
Bladder 1,370 1.40
(1.33-1.48)
310 1.61
(1.43-1.79)
Brain & CNS 31 1.05
(0.71-1.49)
19 0.94
(0.57-1.47)
Thyroid 70 1.47
(1.15-1.86)
145 1.35
(1.14-1.59)
Non-Hodgkin lymphoma 411 1.37
(1.24-1.51)
278 1.36
(1.20-1.53)
Lymphoid leukaemia 297 1.66
(1.48-1.86)
125 1.40
(1.17-1.67)
Myeloid leukaemia 87 1.44
(1.15-1.77)
38 1.25
(0.88-1.71)
Myeloma/PCT 93 1.04
(0.84-1.27)
41 0.89
(0.64-1.21)
Other 992 1.23
(1.16-1.31)
561 1.37
(1.26-1.49)
All cancers combined 14,388 1.22
(1.20-1.24)
9,192 1.36
(1.33-1.39)
Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; n.a. = not applicable; CNS = central nervous system;
PCT = plasma cell tumours. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk.
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a c r o s st h ef o u rt i m ep e r i o d sf o ra l lc a n c e r sc o m b i n e d
(Table 4): 1982-1986 (SIR = 1.14; 95% CI = 1.08-1.20),
1987-1991 (SIR = 1.22; 95% CI = 1.17-1.28), 1992-1996
(SIR = 1.36; 95% CI = 1.31-1.41) and 1997-2001 (SIR =
1.46; 95% CI = 1.41-1.50). In particular, the SIRs for
people with colorectal cancer, lung cancer, breast can-
cer, thyroid cancer, non-Hodgkin lymphoma, lymphoid
Table 3 Relative risk of second primary cancer by type of first primary cancer and age group at first diagnosis,
Queensland, 1982-2006
Age group at first diagnosis
15-49 years 50-64 years 65 years and over
First primary cancer Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Head and neck 223 2.07
(1.80-2.36)
884 2.20
(2.06-2.35)
882 1.77
(1.65-1.89)
Oesophagus 6 4.00
(1.47-8.70)
39 1.70
(1.21-2.32)
60 1.16
(0.88-1.49)
Stomach 17 1.59
(0.93-2.55)
60 1.04
(0.79-1.34)
129 0.91
(0.76-1.08)
Colorectal 188 1.58
(1.36-1.82)
994 1.15
(1.08-1.22)
1,864 1.03
(0.99-1.08)
Pancreas –– 26 1.60
(1.05-2.35)
23 0.61
(0.39-0.92)
Lung 52 2.46
(1.84-3.23)
270 1.55
(1.37-1.74)
407 1.24
(1.12-1.36)
Melanoma 1,121 2.05
(1.94-2.18)
1,755 1.80
(1.72-1.89)
2,216 1.74
(1.67-1.81)
Breast - female 689 1.86
(1.72-2.00)
1,047 1.29
(1.21-1.37)
1,226 1.15
(1.08-1.21)
Cervix 129 1.33
(1.11-1.57)
94 1.49
(1.21-1.83)
77 1.27
(1.01-1.59)
Uterus 47 1.63
(1.20-2.17)
164 1.07
(0.91-1.25)
198 1.16
(1.00-1.33)
Ovary 33 1.25
(0.86-1.76)
64 1.12
(0.87-1.44)
67 1.06
(0.82-1.34)
Prostate 7 0.81
(0.32-1.66)
554 0.87
(0.80-0.95)
2,445 0.82
(0.79-0.85)
Kidney 52 1.63
(1.22-2.14)
230 1.59
(1.39-1.81)
373 1.57
(1.42-1.74)
Bladder 81 2.02
(1.60-2.51)
465 1.63
(1.49-1.79)
1,134 1.70
(1.60-1.80)
Brain & CNS 27 1.64
(1.08-2.39)
15 0.94
(0.52-1.55)
8 0.48
(0.21-0.95)
Thyroid 65 1.22
(0.94-1.55)
84 1.39
(1.11-1.72)
66 1.37
(1.06-1.74)
Non-Hodgkin lymphoma 81 1.60
(1.27-1.99)
261 1.57
(1.39-1.77)
347 1.23
(1.10-1.36)
Lymphoid leukaemia 27 2.68
(1.77-3.90)
131 1.69
(1.42-2.01)
264 1.57
(1.39-1.77)
Myeloid leukaemia 22 2.23
(1.40-3.38)
33 1.39
(0.96-1.95)
70 1.35
(1.05-1.70)
Myeloma/PCT 8 1.40
(0.61-2.77)
47 1.35
(0.99-1.79)
79 0.89
(0.70-1.10)
Other 273 1.69
(1.49-1.90)
472 1.43
(1.30-1.56)
808 1.20
(1.12-1.29)
All cancers combined 3,150 1.84
(1.77-1.90)
7,687 1.39
(1.36-1.42)
12,743 1.23
(1.20-1.25)
Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma
cell tumours. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. SIRs for
pancreatic cancer for the age groups 15-49 years and 50-64 years have been combined due to less than 5 observed cases aged 15-49 years.
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for the later time periods. Among men with prostate
cancer, the risk of developing a second primary cancer
was lower than the incidence of cancer experienced by
males in the general population irrespective of the year
of first diagnosis, except for the latest period (1997-
2001). Several cancer-specific cohorts had SIRs that
were significantly higher than expected in each time
period, including head and neck cancer, melanoma, kid-
ney cancer and bladder cancer.
Relative risk of second primary cancers by follow-up
interval
The risk of a second primary cancer for all survivors
combined remained consistently elevated compared to
the general population during each follow-up interval
(Table 5): 2 months to less than 1 year after first diag-
nosis (SIR = 1.32; 95% CI = 1.27-1.37), 1 year to less
than 5 years (SIR = 1.33; 95% CI = 1.31-1.36), 5 years to
less than 10 years (SIR = 1.39; 95% CI = 1.35-1.42) and
10 years or longer (SIR = 1.28; 95% CI = 1.24-1.31).
A significantly increased relative risk across all follow-
up intervals was also observed following a diagnosis of
head and neck cancer, melanoma, kidney cancer, blad-
der cancer or lymphoid leukaemia, while the risks were
significantly higher from 1 year or longer after diagnosis
for colorectal cancer, lung cancer, female breast cancer
or non-Hodgkin lymphoma. The relative risk of devel-
oping another cancer was significantly higher among
cervical cancer survivors up to 10 years after the initial
diagnosis but not after that. Prostate cancer patients
were found to have subsequent risks that remained
lower than the matching population, particularly 10 or
more years after initial diagnosis.
Relative risk by type of first and second primary cancers
and sex
The relative risks for specific second primary cancers
varied substantially according to the type of first primary
cancer (Figure 1 and 2). Within the melanoma cohort
(Figure 1c and 1d), both males and females were over
six times more likely to be diagnosed with another pri-
mary melanoma compared to the general population.
They also had significantly increased relative risks for
several other cancers, including thyroid cancer and lym-
phoid leukaemia (both males and females), brain cancer,
non-Hodgkin lymphoma, prostate cancer and colorectal
cancer (males only) and kidney cancer and breast cancer
(females only). However, lung cancers occurred less
often than expected among males with a first primary
melanoma.
An elevated relative risk of melanoma was also
observed for both sexes in the colorectal cancer cohort
(Figure 1e and 1f). In addition, male colorectal cancer
survivors had higher risks for lymphoid leukaemia, oeso-
phageal cancer and kidney cancer but a lower risk of
developing a second primary colorectal cancer compared
to the general population, while females with colorectal
cancer experienced a subsequent increased risk of breast
cancer.
Men diagnosed with prostate cancer had significantly
increased relative risks for thyroid cancer, melanoma,
bladder cancer, kidney cancer, non-Hodgkin lymphoma
and colorectal cancer but a significantly decreased risk
of lung cancer (Figure 2a). Instances of primary prostate
cancer occurring twice in the same person were rare.
Female breast cancer survivors were more likely to be
diagnosed with uterine cancer, myeloid leukaemia, sto-
mach cancer, breast cancer, ovarian cancer, melanoma,
kidney cancer or colorectal cancer than were the general
population (Figure 2b).
People initially diagnosed with head and neck cancer
were found to have elevated relative risks for a second
cancer of the head and neck, oesophageal cancer, lung
cancer and non-Hodgkin lymphoma (Figure 2c and
2d). Males with head and neck cancer were also at
increased risk of developing melanoma, colorectal can-
cer or bladder cancer. All lung cancer patients had a
significantly increased risk of oesophageal and head
and neck cancers compared to other residents of
Queensland (Figure 2e and 2f), while males with lung
cancer experienced high relative risks of being subse-
quently diagnosed with kidney, pancreas or bladder
cancers and females with lung cancer had a signifi-
cantly increased risk of developing a second primary
lung cancer. Lymphoid leukaemia occurred less often
among males following lung cancer than in the general
population, although both the observed and expected
number of cases were small.
Discussion
Cancer patients in our study cohort were at significantly
higher risk of a second diagnosis compared to the
underlying incidence rates experienced in the entire
population of Queensland. Although there was some
variation in the size of the estimated relative risks, a
consistent pattern of increased risk following all first
primary cancers combined was seen for both males and
females, and across all age groups at first diagnosis, time
periods of first diagnosis and follow up intervals.
Our data offers further evidence of significant associa-
tions between particular types of first and second pri-
mary cancers that have been previously documented
elsewhere in Australia and around the world [6,12-16].
Some examples include the mutual increased risks
between head and neck, lung and oesophageal cancers
and the relationship between melanoma and both pros-
tate and female breast cancers.
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Queensland, 1982-2006
Time period of first diagnosis
1982-1986 1987-1991 1992-1996 1997-2001
First primary cancer Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Head and neck 165 1.92
(1.64-2.23)
204 1.88
(1.63-2.16)
271 1.98
(1.75-2.23)
255 1.93
(1.70-2.18)
Oesophagus 8 1.53
(0.66-3.02)
10 0.90
(0.43-1.66)
23 1.60
(1.01-2.39)
23 1.19
(0.76-1.79)
Stomach 18 0.75
(0.44-1.18)
27 1.02
(0.67-1.49)
30 0.91
(0.62-1.31)
36 1.09
(0.76-1.51)
Colorectal 198 0.89
(0.77-1.02)
273 0.95
(0.84-1.07)
411 1.07
(0.97-1.18)
559 1.20
(1.11-1.31)
Pancreas 7 1.20
(0.48-2.47)
5 0.61
(0.20-1.42)
10 0.98
(0.47-1.81)
12 0.83
(0.43-1.45)
Lung 71 1.06
(0.83-1.34)
93 1.14
(0.92-1.40)
147 1.61
(1.36-1.89)
148 1.30
(1.10-1.53)
Melanoma 311 1.81
(1.62-2.02)
471 1.89
(1.72-2.07)
639 2.04
(1.88-2.20)
835 2.02
(1.89-2.16)
Breast - female 152 0.97
(0.82-1.14)
199 0.94
(0.81-1.08)
359 1.32
(1.19-1.47)
504 1.37
(1.25-1.50)
Cervix 24 1.29
(0.83-1.92)
38 1.88
(1.33-2.58)
34 1.64
(1.14-2.29)
26 1.55
(1.01-2.27)
Uterus 30 1.14
(0.77-1.63)
35 1.18
(0.82-1.64)
35 0.87
(0.60-1.21)
63 1.30
(0.99-1.66)
Ovary 16 1.36
(0.78-2.20)
10 0.64
(0.31-1.18)
26 1.35
(0.88-1.98)
24 1.02
(0.66-1.52)
Prostate 163 0.64
(0.54-0.74)
291 0.76
(0.68-0.85)
603 0.84
(0.77-0.91)
655 0.95
(0.88-1.02)
Kidney 44 1.48
(1.08-1.99)
73 1.79
(1.40-2.25)
92 1.53
(1.24-1.88)
160 2.04
(1.74-2.38)
Bladder 137 1.46
(1.22-1.72)
189 1.78
(1.53-2.05)
238 1.84
(1.61-2.09)
353 2.22
(2.00-2.47)
Brain & CNS ––5 1.00
(0.33-2.34)
––9 1.10
(0.50-2.09)
Thyroid 9 1.25
(0.57-2.38)
12 1.25
(0.64-2.18)
29 1.64
(1.10-2.36)
46 1.67
(1.22-2.23)
Non-Hodgkin lymphoma 42 1.09
(0.79-1.48)
62 1.15
(0.88-1.48)
88 1.25
(1.00-1.54)
144 1.49
(1.25-1.75)
Lymphoid leukaemia 24 1.00
(0.64-1.48)
33 1.25
(0.86-1.75)
63 1.68
(1.29-2.15)
88 1.71
(1.37-2.10)
Myeloid leukaemia 13 1.23
(0.66-2.11)
11 0.91
(0.45-1.62)
26 1.52
(0.99-2.22)
34 2.05
(1.42-2.86)
Myeloma/PCT 21 1.37
(0.85-2.10)
7 0.46
(0.19-0.95)
19 0.83
(0.50-1.29)
39 1.05
(0.75-1.44)
Other 79 0.94
(0.74-1.17)
136 1.22
(1.03-1.45)
241 1.43
(1.26-1.62)
318 1.43
(1.28-1.60)
All cancers combined 1,534 1.14
(1.08-1.20)
2,184 1.22
(1.17-1.28)
3,386 1.36
(1.31-1.41)
4,331 1.46
(1.41-1.50)
Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma
cell tumours. Analysis by period of first diagnosis was restricted to five years of follow-up to allow more consistent comparisons across time. SIRs shown in
normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. Estimates are not shown for Brain & CNS for
the periods 1982-1986 and 1992-1996 due to observed cell counts of less than 5.
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Page 7 of 12Table 5 Relative risk of second primary cancer by type of first primary cancer and follow-up interval, Queensland,
1982-2006
Follow-up interval
2 months to less than 1 year 1 year to less than 5 years 5 years to less than 10 years 10 years or longer
First primary cancer Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Obs. SIR
(95% CI)
Head and neck 164 1.67
(1.42-1.95)
731 2.00
(1.86-2.15)
651 2.10
(1.94-2.26)
443 1.89
(1.72-2.08)
Oesophagus 22 1.22
(0.77-1.85)
42 1.31
(0.95-1.77)
32 1.76
(1.20-2.48)
9 1.11
(0.51-2.10)
Stomach 36 0.97
(0.68-1.35)
75 0.95
(0.74-1.18)
55 1.04
(0.78-1.35)
40 0.99
(0.71-1.35)
Colorectal 310 1.03
(0.92-1.16)
1,131 1.07
(1.01-1.13)
912 1.11
(1.04-1.18)
693 1.14
(1.06-1.23)
Pancreas 14 0.74
(0.40-1.24)
20 1.01
(0.62-1.57)
15 0.99
(0.55-1.64)
––
Lung 147 1.06
(0.89-1.24)
312 1.46
(1.30-1.63)
183 1.71
(1.47-1.98)
87 1.35
(1.08-1.67)
Melanoma 458 2.15
(1.95-2.35)
1,798 1.92
(1.84-2.02)
1,553 1.80
(1.71-1.89)
1,283 1.63
(1.55-1.73)
Breast - female 194 1.02
(0.88-1.18)
1,020 1.25
(1.17-1.33)
1,019 1.44
(1.35-1.53)
729 1.36
(1.26-1.46)
Cervix 33 2.13
(1.46-2.99)
89 1.46
(1.18-1.80)
89 1.43
(1.15-1.76)
89 1.09
(0.87-1.34)
Uterus 29 1.03
(0.69-1.48)
134 1.15
(0.96-1.36)
147 1.36
(1.15-1.60)
99 1.00
(0.81-1.21)
Ovary 22 1.22
(0.77-1.85)
54 1.04
(0.78-1.35)
46 1.18
(0.86-1.57)
42 1.11
(0.80-1.50)
Prostate 344 0.81
(0.73-0.90)
1,368 0.84
(0.80-0.89)
988 0.88
(0.82-0.93)
306 0.66
(0.59-0.74)
Kidney 115 2.45
(2.02-2.94)
254 1.57
(1.38-1.77)
177 1.42
(1.22-1.65)
109 1.35
(1.11-1.63)
Bladder 249 2.40
(2.11-2.72)
668 1.73
(1.61-1.87)
477 1.61
(1.47-1.76)
286 1.39
(1.23-1.56)
Brain & CNS 6 0.60
(0.22-1.31)
12 0.77
(0.40-1.34)
18 1.44
(0.85-2.28)
14 1.28
(0.70-2.15)
Thyroid 18 1.65
(0.98-2.61)
78 1.53
(1.21-1.91)
63 1.21
(0.93-1.55)
56 1.16
(0.87-1.50)
Non-Hodgkin lymphoma 74 1.23
(0.97-1.55)
262 1.31
(1.16-1.48)
209 1.46
(1.27-1.67)
144 1.49
(1.26-1.76)
Lymphoid leukaemia 52 1.82
(1.36-2.39)
156 1.40
(1.19-1.64)
143 1.89
(1.59-2.23)
71 1.78
(1.37-2.22)
Myeloid leukaemia 27 1.59
(1.05-2.31)
57 1.44
(1.09-1.87)
28 1.40
(0.93-2.03)
13 1.41
(0.75-2.41)
Myeloma/PCT 18 0.76
(0.45-1.21)
68 1.02
(0.79-1.29)
36 1.26
(0.88-1.74)
12 1.12
(0.58-1.95)
Other 179 1.22
(1.05-1.42)
595 1.35
(1.25-1.47)
447 1.36
(1.24-1.49)
332 1.33
(1.19-1.48)
All cancers combined 2,511 1.32
(1.27-1.37)
8,924 1.33
(1.31-1.36)
7,286 1.39
(1.35-1.42)
4,859 1.28
(1.24-1.31)
Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma
cell tumours. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. SIRs for
pancreatic cancer for 5 years to less than 10 years after first diagnosis and 10 years or longer after first diagnosis have been combined due to less than 5
observed cases 10 years or longer after first diagnosis.
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Page 8 of 12Much of the elevated risk of being diagnosed with a
second malignancy can be attributed to risk behaviours
(such as smoking, harmful levels of alcohol consumption
and poor diet), inherited susceptibilities and/or the med-
ical treatment that cancer survivors have received
[3,4,6]. On occasions, treatment can also have the oppo-
site effect of reducing the risko fs u b s e q u e n td i a g n o s i s .
As was noted in another recent study of second primary
cancer [13], the overall lower SIRs observed among
prostate cancer survivors are mainly due to extremely
a. All cancers – Males 
 
b. All cancers – Females 
c. Melanoma – Males 
 
d. Melanoma – Females 
e. Colorectal cancer – Males  f. Colorectal cancer – Females 
Figure 1 Relative risk following all cancers combined, melanoma or colorectal cancer by type of second primary cancer and sex,
Queensland, 1982-2006. CNS: central nervous system; PCT: plasma cell tumour.Vertical black line indicates SIR point estimate; grey shading
indicates SIR 95% confidence interval. X-axes are shown on a log scale.
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Page 9 of 12a. Prostate cancer – Males 
 
b. Breast cancer – Females 
c. Head and neck cancer – Males 
 
d. Head and neck cancer – Females 
e. Lung cancer – Males  f. Lung cancer – Females 
Figure 2 Relative risk following prostate cancer, breast cancer, head and neck cancer or lung cancer by type of second primary
cancer and sex, Queensland, 1982-2006. CNS: central nervous system; PCT: plasma cell tumour. Vertical black line indicates SIR point estimate;
grey shading indicates SIR 95% confidence interval. The SIR for a second primary prostate cancer following a first primary prostate cancer was
0.3 and is not shown in Figure 2a. No cases of lymphoid leukaemia following head and neck cancer were recorded for females (Figure 2d). X-
axes are shown on a log scale. Note different scale endpoints for x-axis used in Figures 2d, 2e and 2f.
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Page 10 of 12low rates of reoccurrence as the organ is often comple-
tely removed as part of treatment. Given that prostate
cancer is the most common cancer diagnosed for males
in Queensland, this also helps to explain why the total
relative risk is lower for male survivors compared to
female survivors.
Another potential explanation for the difference in
risk between cancer survivors and the general popula-
tion is that some demographic factors may not be com-
parable between the two groups. Although the relative
risks were based on calculations matched by sex, age
group and time period, it is possible that other qualities,
such as socioeconomic status, may vary between people
who have been diagnosed with cancer and those who
have not. This is likely to be the reason for at least part
of the reduced risk of lung cancer (which has higher
incidence among lower socioeconomic groups) for
males following melanoma (which is more common in
segments of the community with higher socioeconomic
status) [6,17]. A similar explanation could be used for
the deficit of lung cancer after a diagnosis of prostate
cancer. In contrast, the high reciprocal relative risks of
melanoma with both female breast cancer and prostate
cancer may correlate with the higher incidence for each
of these malignancies among more affluent populations
[18-20].
One of the interesting relationships that emerged from
the analysis was the variation in relative risk of second
primary cancer by age at first diagnosis following cancer
of the brain and central nervous system. Younger survi-
vors (15-49 years old) had an increased risk of being
diagnosed with a second primary cancer while survivors
aged 65 years or over had a decreased risk. This is most
likely due to the various histopathological subtypes of
brain tumours which are more common in the different
age groups. For example, glioblastoma tends to be diag-
nosed at an older age and is associated with poor survi-
val, allowing a limited time for treatment-related second
primary cancers to appear [6].
The reasons behind an increased relative risk of sec-
ond primary cancer following certain types of cancer
among survivors who were diagnosed more recently are
unknown. Tsukuma et al. [16] described a similar pat-
tern in Japan, and suggested that apparent increases in
risk may be due to improved follow-up and surveillance
of cancer patients. Another possible cause is the change
in treatment modalities over time [4,21].
Second primary cancers that arise due to the effects of
treatment for the initial cancer might be expected to
occur many years after the first diagnosis. However, the
increase in relative risk remained fairly consistent irre-
spective of time since diagnosis, in accordance with
results published elsewhere in Australia [13] and the
United States [6].
The main strengths of this study include the extensive
population-based coverage achieved by the QCR for the
reporting of cancers among Queensland residents, com-
bined with a high level of histological verification (88%
in 2006) [8], which is important for distinguishing
between new primary cancers and metastases of an
existing cancer. Since all data used in this study have
been collected prospectively for administrative purposes,
and coded independently of the hypotheses, the oppor-
tunity for recall or information bias has been removed.
Increased medical surveillance of newly-diagnosed
cancer patients may introduce a detection bias for sec-
ond primary cancers. The likelihood of this happening
has been reduced by only considering metachronous
primary cancers, with a two-month window between
first and second diagnosis. It is also possible that some
second primary cancers were incorrectly classified as
first primary cancers, especially for cancers diagnosed
soon after the establishment of the QCR in the early
1 9 8 0 s ;w ea r eu n a b l et oq u a n t i f yt h ei m p a c to ft h i so n
the observed results.
While acknowledging that the study cohort and com-
parison population were not independent, with the
population containing people already diagnosed with
cancer, this proportion was less than 0.5% in any given
year. Finally, as a result of the large number of compari-
sons made, the possibility that some of the SIR esti-
mates have been spuriously identified as statistically
significant needs to be considered, particularly those
based on small numbers of primary or secondary can-
cers, and these results should therefore be interpreted
with due caution.
Conclusions
Our results demonstrate that cancer survivors in
Queensland, Australia, like those in other countries, are
confronted by a very real, ongoing risk of developing a
second primary cancer that is significantly higher than
the incidence of cancer experienced by the general
population. Some first and second primary cancers
share common aetiologies, making it imperative that
cancer patients adopt a healthier lifestyle in order to les-
sen their chances of subsequent diagnoses [4,22]. Recent
studies have reported little difference in the health beha-
viours of cancer survivors compared to the wider com-
munity [23-25], suggesting that health promotion efforts
may need to be specifically targeted at people diagnosed
with cancer due to their subsequent increased risk.
Further work is needed to determine exactly how bene-
ficial changes to lifestyle may be in regard to the risk of
developing a second primary cancer [26]. Even so, some
second primary cancers will be unavoidable, and as the
number of cancer survivors continues to grow,
the importance of ongoing medical supervision and
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Page 11 of 12screening to detect second primary cancers at an earlier
stage and thereby improve the effectiveness of treatment
will remain critical.
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